Coya Therapeutics, Inc. (NASDAQ:COYA) Short Interest Up 7.3% in September

Coya Therapeutics, Inc. (NASDAQ:COYA) saw a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 173,600 shares, a growth of 7.3% from the August 31st total of 161,800 shares. Based on an average daily trading volume, of 44,800 shares, the short-interest ratio is presently 3.9 days. Currently, 1.2% of the company’s stock are sold short.

Coya Therapeutics Trading Up 7.6 %

COYA stock opened at $6.76 on Monday. Coya Therapeutics has a 1-year low of $3.21 and a 1-year high of $10.69. The business’s 50 day simple moving average is $6.14 and its 200 day simple moving average is $7.37. The firm has a market capitalization of $98.82 million, a PE ratio of -7.95 and a beta of 0.58.

Coya Therapeutics (NASDAQ:COYA) last announced its earnings results on Monday, August 12th. The company reported ($0.19) EPS for the quarter. The company had revenue of $3.43 million for the quarter. As a group, sell-side analysts predict that Coya Therapeutics will post -1.27 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. HC Wainwright assumed coverage on Coya Therapeutics in a research report on Monday, September 16th. They set a “buy” rating and a $18.00 price target for the company. Rodman & Renshaw assumed coverage on shares of Coya Therapeutics in a report on Thursday, June 13th. They set a “buy” rating and a $18.00 target price for the company. Finally, Chardan Capital reiterated a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Wednesday, June 5th.

Institutional Trading of Coya Therapeutics

Several institutional investors have recently added to or reduced their stakes in COYA. Gilbert & Cook Inc. bought a new position in shares of Coya Therapeutics during the second quarter worth approximately $61,000. Renaissance Technologies LLC acquired a new position in Coya Therapeutics in the 2nd quarter valued at $101,000. Vanguard Group Inc. lifted its position in shares of Coya Therapeutics by 772.3% during the 1st quarter. Vanguard Group Inc. now owns 847,490 shares of the company’s stock valued at $8,407,000 after acquiring an additional 750,338 shares during the period. Finally, Greenlight Capital Inc. grew its holdings in shares of Coya Therapeutics by 172.2% during the 4th quarter. Greenlight Capital Inc. now owns 1,274,026 shares of the company’s stock worth $9,441,000 after purchasing an additional 805,959 shares in the last quarter. 39.75% of the stock is currently owned by institutional investors.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.